

Neofunction of ACVR1 in fibrodysplasia ossificans progressiva

Kyosuke Hino^{a,b}, Makoto Ikeya^{a,1}, Kazuhiko Horigome^{a,b}, Yoshihisa Matsumoto^{a,c,d}, Hayao Ebise^e, Megumi Nishio^a, Kazuya Sekiguchi^{a,c,f}, Mitsuaki Shibata^a, Sanae Nagata^a, Shuichi Matsuda^f, and Junya Toguchida^{a,c,f,1}

^aDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan; ^biPS Cell-Based Drug Discovery Group, Innovative Drug Discovery Laboratories, Sumitomo Dainippon Pharma Co., Ltd., Osaka, 554-0022, Japan; ^cDepartment of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, 606-8507, Japan; ^dDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, 467-8601, Japan; ^eOmics Group, Genomic Science Laboratories, Sumitomo Dainippon Pharma Co., Ltd., Osaka, 554-0022, Japan; and ^fDepartment of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

Edited by Stephen T. Warren, Emory University School of Medicine, Atlanta, GA, and approved October 28, 2015 (received for review June 3, 2015)

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by extraskeletal bone formation through endochondral ossification. FOP patients harbor point mutations in ACVR1 (also known as ALK2), a type I receptor for bone morphogenetic protein (BMP). Two mechanisms of mutated ACVR1 (FOP-ACVR1) have been proposed: ligand-independent constitutive activity and ligand-dependent hyperactivity in BMP signaling. Here, by using FOP patient-derived induced pluripotent stem cells (FOP-iPSCs), we report a third mechanism, where FOP-ACVR1 abnormally transduces BMP signaling in response to Activin-A, a molecule that normally transduces TGF- β signaling but not BMP signaling. Activin-A enhanced the chondrogenesis of induced mesenchymal stromal cells derived from FOP-iPSCs (FOP-iMSCs) via aberrant activation of BMP signaling in addition to the normal activation of TGF- β signaling in vitro, and induced endochondral ossification of FOP-iMSCs in vivo. These results uncover a novel mechanism of extraskeletal bone formation in FOP and provide a potential new therapeutic strategy for FOP.

iPSC | fibrodysplasia ossificans progressiva | heterotopic ossification | BMP | TGF

Heterotopic ossification (HO) is defined as bone formation in soft tissue where bone normally does not exist. It can be the result of surgical operations, trauma, or genetic conditions, one of which is fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disease characterized by extraskeletal bone formation through endochondral ossification (1–6). The responsive mutation for classic FOP is 617G > A (R206H) in the intracellular glycine- and serine-rich (GS) domain (7) of ACVR1 (also known as ALK2), a type I receptor for bone morphogenetic protein (BMP) (8–10). ACVR1 mutations in atypical FOP patients have been found also in other amino acids of the GS domain or protein kinase domain (11, 12). Regardless of the mutation site, mutated ACVR1 (FOP-ACVR1) has been shown to activate BMP signaling without exogenous BMP ligands (constitutive activity) and transmit much stronger BMP signaling after ligand stimulation (hyperactivity) (12–25).

To reveal the molecular nature of how FOP-ACVR1 activates BMP signaling, cells overexpressing FOP-ACVR1 (12–20), mouse embryonic fibroblasts derived from *Alk2*^{R206H/+} mice (21, 22), and cells from FOP patients, such as stem cells from human exfoliated deciduous teeth (23), FOP patient-derived induced pluripotent stem cells (FOP-iPSCs) (24, 25) and induced mesenchymal stromal cells (iMSCs) from FOP-iPSCs (FOP-iMSCs) (26) have been used as models. Among these cells, *Alk2*^{R206H/+} mouse embryonic fibroblasts and FOP-iMSCs are preferred because of their accessibility and expression level of FOP-ACVR1 using an endogenous promoter. In these cells, however, the constitutive activity and hyperactivity is not strong (within twofold normal levels) (22, 26). In addition, despite the essential role of BMP signaling in development (27–31), the pre- and postnatal development and growth of FOP patients are almost normal, and HO is induced in FOP patients after physical trauma and inflammatory response postnatally, not at birth

(1–6). These observations led us to hypothesize that FOP-ACVR1 abnormally responds to noncanonical BMP ligands induced by trauma or inflammation.

Here we show that FOP-ACVR1 transduced BMP signaling in response to Activin-A, a molecule that normally transduces TGF- β signaling (10, 32–34) and contributes to inflammatory responses (35, 36). Our in vitro and in vivo data indicate that activation of TGF- β and aberrant BMP signaling by Activin-A in FOP-cells is one cause of HO in FOP. These results suggest a possible application of anti-Activin-A reagents as a new therapeutic tool for FOP.

Results

Activin-A Abnormally Transduced BMP Signaling in FOP-iMSCs, but Not in resFOP-iMSCs. To screen noncanonical BMP ligands that activate BMP signaling through FOP-ACVR1 but not through WT-ACVR1, we focused our attention on FOP-iMSCs from FOP patient-derived iPSCs as test cells and mutation-rescued FOP-iMSCs (resFOP-iMSCs) as genetically matched control cells (26). A BMP-specific luciferase reporter construct (BRE-Luc) was transfected into both FOP-iMSCs and resFOP-iMSCs, and detection of luminescence was made 16 h after ligand stimulation (Fig. 1A). Consistent with previous reports (14, 18), several BMP ligands, such as BMP-6 and BMP-7, induced higher luminescence in FOP-iMSCs than resFOP-iMSCs, but at less than 1.4-fold (Fig. 1B and *SI Appendix, Fig. S1*). Interestingly,

Significance

By utilizing patient-specific induced pluripotent stem cells (iPSCs) of fibrodysplasia ossificans progressiva (FOP) and gene-corrected (rescued) FOP-iPSCs, we discovered a novel mechanism in ectopic bone formation: The disease-causing mutation endows ACVR1 with the ability to transmit the signal of an unexpected ligand, Activin-A. We believe this is a milestone study for FOP research and provides a novel platform for searching therapeutic targets of this intractable disease.

Author contributions: K. Hino, M.I., and J.T. designed research; K. Hino, K. Horigome, Y.M., H.E., M.N., K.S., M.S., and S.N. performed research; M.I., K. Horigome, and S.M. contributed new reagents/analytic tools; K. Hino, M.I., K. Horigome, Y.M., H.E., and M.N. analyzed data; and K. Hino, M.I., and J.T. wrote the paper.

Conflict of interest statement: K. Hino, K. Horigome, and H.E. are employees of Sumitomo Dainippon Pharma Co., Ltd; and M.I. and J.T. are supported by a research fund from Sumitomo Dainippon Pharma Co., Ltd.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession nos. GSE62783 and GSE69459).

¹To whom correspondence may be addressed. Email: mikeya@cira.kyoto-u.ac.jp or togjun@frontier.kyoto-u.ac.jp.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1510540112/-DCSupplemental.




Fig. 1. Activin-A abnormally transduced BMP signaling in FOP-iMSCs. (A) Scheme of FOP-ACVR1 specific ligand screening. (B) Activin-A caused the highest increase in BRE-Luc activity (FOP/resFOP) among TGF- β superfamily ligands tested. (C) Activin-A increased BRE-Luc activity in FOP-iMSCs, but not in resFOP-iMSCs. (D) Representative image of Western blot analysis. Activin-A induced phosphorylation of SMAD1/5/8 (p-SMAD1) in FOP-iMSCs, but not in resFOP-iMSCs. After 6-h serum starvation, FOP- and resFOP-iMSCs were treated with ligands for 1 h. (E) Quantification of relative p-SMAD1/5/8 phosphorylation levels corrected by total SMAD1/5/8. (F) Higher expression levels of BMP target genes in FOP-iMSCs stimulated with Activin-A in microarray analysis. (G–I) Global gene expression analysis showed Activin-A transduced BMP signaling in FOP-iMSCs. Hierarchical clustering analysis (G) and a PCA plot (H) of FOP- and resFOP-iMSCs using differentially expressed gene sets. (I) Ingenuity pathway analysis using genes differentially expressed between FOP- and resFOP-iMSC treated with Activin-A. Results are the mean $\pm$ SE. $n = 3$ –4 (BRE-Luc assay) and $n = 3$ (Western blot and microarray analysis). n.s., no significant difference; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ by Dunnett's multiple comparisons t test compared with the no ligand treatment control (B) and by Student's t test compared with resFOP-iMSCs treated with the same ligands (C, E, and F). ActA, 100 ng/mL Activin-A; BMP, 100 ng/mL BMP-7; TGF, 10 ng/mL TGF- β 3 (D–I).

Activin-A treatment significantly increased the luciferase activity in FOP-iMSCs, but not in resFOP-iMSCs (Fig. 1B and C and *SI Appendix, Fig. S1*). This result was confirmed in another rescue clone and another patient-derived FOP- and resFOP-iMSCs (*SI Appendix, Fig. S2*). The phosphorylation of SMAD1/5/8, cytoplasmic BMP signaling transducers, and the expression of downstream genes of BMP signaling were also induced specifically in FOP-iMSCs (Fig. 1D–F). Global gene-expression profiling revealed that Activin-A treatment substantially transduced BMP-like signaling in FOP-iMSCs, but not in resFOP-iMSCs (Fig. 1G–I). These results indicated that Activin-A abnormally transduced BMP signaling in FOP-iMSCs.

Molecular Mechanisms of Abnormal BMP Signaling Evoked by Activin-A.

Next, to check the necessity and sufficiency of FOP-ACVR1 on BMP signaling, loss-of-function and gain-of-function studies were performed. Treatment of siRNAs specific for type I receptors in FOP-iMSCs revealed a critical requirement of FOP-ACVR1 in Activin-A-dependent BMP signaling (Fig. 2A; knockdown efficiencies are shown in *SI Appendix, Fig. S3*). Treatment of siRNAs specific for type II receptors showed the involvement of both ACVR2A and BMPR2 in this abnormal activation (Fig. 2B and *SI Appendix, Fig. S3*). Conversely, overexpression of the mutant ACVR1 found in FOP patients conferred Activin-A responsiveness in U2OS cells (Fig. 2C). This neofunction of FOP-ACVR1 was also confirmed in HEK293 and HepG2 cells (*SI Appendix, Fig. S4*). These results indicated that Activin-A activates abnormal BMP signaling through FOP-ACVR1.

Because Activin-A normally transduces TGF- β –SMAD2/3 signaling (10, 32–34), the phosphorylation of SMAD2/3 and activation of a TGF- β -responsive luciferase reporter construct (CAGA-Luc) were analyzed. The levels of phosphorylation and activation in FOP-iMSCs were similar to those in resFOP-iMSCs (*SI Appendix, Fig. S5*). Knockdown experiments revealed the involvement of ACVR1B and ACVR2A in this signaling (*SI Appendix, Fig. S6*). These results indicated that Activin-A transduces TGF- β –SMAD2/3 signaling through ACVR1B/ACVR2A in FOP-iMSCs.

To dissect the molecular mechanism of how FOP-ACVR1 transduces abnormal BMP signaling, we assessed to which receptors Activin-A was potentially bound. Treatment of the soluble extracellular region of FOP-ACVR1 (ACVR1-Fc; same as WT-ACVR1) did not affect the Activin-A-dependent activation of BRE-Luc in FOP-iMSCs (Fig. 2D), whereas treatment of ACVR2A-Fc and ACVR2B-Fc strongly and BMPR2-Fc weakly decreased the activity (Fig. 2E). Because knockdown experiments indicated signal transduction of Activin-A on BMP signaling through FOP-ACVR1, these results suggested that Activin-A is indirectly bound to FOP-ACVR1. Next, we checked whether the binding affinity of FOP-ACVR1 to Activin-A with or without type II receptors is altered. Cross-linking experiments revealed that the binding affinity was slightly enhanced when either ACVR2A or ACVR2B was coexpressed (Fig. 2F). FOP mutations are found in the intracellular region of ACVR1 around the regulatory GS domain and protein kinase domain, and thought to destabilize the inactive state of ACVR1 through the binding of inhibitory protein FKBP12 (12, 15, 17, 37). Thus, we checked whether treatment of FK506, an inhibitor of FKBP12, conferred Activin-A-dependent activation of BMP signaling in resFOP-iMSCs. As expected, treatment of FK506 rendered the responsiveness of Activin-A in resFOP-iMSCs (Fig. 2G), although FK506 enhanced the constitutive activity in FOP-iMSCs (*SI Appendix, Fig. S7*). Taken together, the abnormal reactivity of FOP-ACVR1 to Activin-A could be caused, at least partially, by differential affinity for Activin-A and the dysregulation of inhibitory mechanisms. However, further investigation is required for more detailed understanding of the aberrant activation of BMP signaling by Activin-A.

Enhanced Chondrogenesis of FOP-iMSCs via BMP and TGF- β Signaling by Activin-A Stimulation.

Because HO occurs through endochondral ossification in FOP patients (1–6) and pathway analysis of FOP-iMSCs revealed that Activin-A induces chondrogenic pathways in FOP-iMSCs (Fig. 1I), the impact of Activin-A on chondrogenesis was assessed. After treatment of chondrogenic basal medium with TGF- β 3 for 7 d, we found the glycosaminoglycan (GAG) production/DNA ratio (GAG/DNA) in 2D micromass of FOP-iMSCs was comparable to that of resFOP-iMSCs (Fig. 3A and B).




Fig. 2. Molecular mechanisms of abnormal BMP signaling evoked by Activin-A. (A and B) Activin-A transduced FOP-ACVR1-mediated BMP signaling through ACVR2A and BMPR2. FOP-iMSCs transiently transfected with BRE-Luc, CMV-*Renilla*, and siRNAs specific for type I receptors (A) or type II receptors (B) were stimulated with Activin-A for 16 h. Note, neither ACVR1C nor AMHR2 were expressed in FOP-iMSCs. (C) Other FOP mutant receptors also transduced BMP signaling by Activin-A stimulation. U2OS cells transiently transfected with BRE-Luc, CMV-*Renilla*, and FOP mutant receptors were stimulated with 20 ng/mL Activin-A or 10 ng/mL BMP-7 for 16 h. (D and E) Activin-A strongly bound to the extracellular region of ACVR2A, 2B and weakly to BMPR2, but not to ACVR1. (F) Binding of ¹²⁵I-Activin-A to LentiX293T transfected with hACVR1-V5, SNAP-hACVR2A, SNAP-hACVR2B, or hBMPR2. Cells were affinity labeled with ¹²⁵I-Activin-A and cross-linked by disuccinimidyl suberate. Type II R, Type II receptors. (G) resFOP-iMSCs acquired Activin-A responsiveness by FK506 treatment. resFOP-iMSCs transiently transfected with BRE-Luc and CMV-*Renilla* were treated with 1 μ M FK506 or Activin-A for 16 h. n.s., no significant difference; * P < 0.05; ** P < 0.01; *** P < 0.001 by Dunnett's multiple comparisons t test compared with the control siRNA transfected FOP-iMSCs (A and B), to the no ligand treatment controls transfected with the same receptors (C), or to the no Fc-fusion receptors treatment control (D and E), and by Student's t test (G). Results are the mean $\pm$ SE. n = 4–8.

Treatment of BMP-7 induced slightly higher GAG/DNA in FOP-iMSCs compared with resFOP-iMSCs, consistent with the idea that cells expressing FOP-ACVR1 have higher sensitivity for BMP ligands. These results also indicated that both TGF- β and BMP signaling play critical roles for chondrogenesis in the 2D micromass assay of both FOP-iMSCs and resFOP-iMSCs. In sharp contrast, treatment of Activin-A induced significantly higher GAG/DNA in FOP-iMSCs compared with resFOP-iMSCs. We also found Activin-A treatment increased the expression of chondrogenic markers (*ACAN*, *COL2A1*, and *SOX9*) in FOP-iMSCs (Fig. 3C), indicating that Activin-A treatment is sufficient to induce enhanced chondrogenesis in these cells. To verify the accuracy of our FOP-iMSCs model, we performed a 2D-chondrogenic assay with retinoic acid receptor- γ agonists

(CD437 and R667) (38, 39) and confirmed reduction of GAG/DNA in a concentration-dependent manner (SI Appendix, Fig. S8).

To gain molecular insights underlying the enhanced chondrogenesis, unbiased transcriptome analysis of FOP-iMSCs and resFOP-iMSC with or without Activin-A treatment was performed. We identified two BMP signaling components, BMP4 and BMP9, as upstream regulators in FOP-iMSCs (Fig. 3D, Right), consistent with the fact that Activin-A abnormally transduces BMP signaling in FOP-iMSCs. This analysis also identified TGF- β 1 and BMPR1A as upstream regulators in FOP-iMSCs and resFOP-iMSCs treated with Activin-A (Fig. 3D, Left and Center), indicating that BMP signaling as well as TGF- β signaling were activated not only in FOP-iMSCs, but also resFOP-iMSCs during chondrogenesis, even though short-term administration of Activin-A did not induce BMP-SMAD1/5/8 signaling in resFOP-iMSCs (Fig. 1 C–F).




Fig. 3. Enhanced chondrogenesis of 2D chondrogenic micromass of FOP-iMSCs by Activin-A stimulation, which was suppressed by Activin-A inhibitors. (A–G) Two-dimensional chondrogenic micromass assay of FOP- and resFOP-iMSCs at day 7. (A) Representative images of Alcian blue staining. (Scale bar, 200 μ m.) (B) Enhanced GAG/DNA in the micromass of FOP-iMSCs cultured with Activin-A, and which was inhibited by 1 μ M DMH1 or 1 μ M SB431542 (SB) treatment. TGF, 1 ng/mL TGF- β 1. (C) Higher expression levels of early chondrogenic markers (*ACAN*, *COL2A1*, and *SOX9*) in the micromass of FOP-iMSCs cultured with Activin-A. (D) Upstream analysis using genes up- or down-regulated at least twofold after chondrogenic differentiation with or without Activin-A. (E) DMH1 (1 μ M), but not SB (1 μ M) inhibit the expression of BMP downstream target genes 16 h after stimulation by Activin-A. (F and G) Activin-A-triggered enhanced chondrogenesis of FOP-iMSCs was inhibited by several Activin-A inhibitors. Results are the mean $\pm$ SE. n = 4 (B, C, G), n = 3 (E), and n = 1 (D). n.s., no significant difference; * P < 0.05; ** P < 0.01; *** P < 0.001 by Student's t test compared with resFOP treated with the same ligands with or without the same compounds (B and C) and by Dunnett's multiple comparisons t test compared with Activin-A-treated FOP-iMSCs (E) or Activin-A-treated micromass without Activin-A inhibitors (G).

Because our data indicated that both BMP and TGF- β signaling were activated in Activin-A-treated FOP-iMSCs during chondrogenesis (Fig. 3*D, Center*), a specific inhibitor of either BMP signaling (DMH1) or TGF- β signaling (SB431542) was administered to discriminate the involvement of these two signaling pathways in the observed enhanced chondrogenesis. Treatment of DMH1 diminished enhanced GAG/DNA in FOP-iMSCs (Fig. 3*A* and *B*), consistent with Activin-A abnormally transducing BMP signaling in FOP-iMSCs. Intriguingly, treatment of SB431542 also abrogated enhanced GAG/DNA in FOP-iMSC, but did not decrease the level of two downstream BMP signaling targets, *ID1* and *ID3* (Fig. 3*E*), suggesting that the abrogation was not caused by a side effect of SB431542 on BMP signaling. Taken together, these results strongly suggest that the enhanced chondrogenesis in FOP-iMSCs is caused by the dual activation of BMP and TGF- β signaling via the administration of Activin-A.

In addition to chemical cytoplasmic inhibitors, administration of extracellular Activin-A inhibitors, such as Follistatin-related gene protein, Follistatin, anti-Activin-A Ab, ACVR2A-Fc (2A-Fc), and ACVR2B-Fc (2B-Fc), also significantly suppressed the Activin-A dependent enhancement of chondrogenesis (Fig. 3*F* and *G*). These results indicated that Activin-A inhibitors have the potential to become new therapeutic agents.

Enhanced Calcification of FOP-3DCI Pellets in Vivo. Although the 2D micromass assay is suitable for the verification of exogenous factors, the 3D chondrogenic induction (3DCI) pellet assay enables the analysis of more mature chondrocytes in vitro and also allows the transplantation of the pellets in vivo. After culture in chondrogenic basal medium with TGF- β 3, BMP-7, or Activin-A for 17 d, GAG/DNA of 3DCI pellets from FOP-iMSCs (FOP-3DCI pellets) were observed as comparable, slightly higher, and markedly higher than those from resFOP-iMSCs (resFOP-3DCI pellets), respectively (Fig. 4*A*), consistent with the results from the 2D micromass culture (Fig. 3*A* and *B*). Histological analyses revealed that the FOP-3DCI pellets cultured with Activin-A contained more mature chondrocytes than did resFOP-3DCI pellets (Fig. 4*B*). Quantitative PCR analysis revealed that markers for mature chondrocytes (40), such as *COL10A1*, *VEGFA*, *RUNX2*, and *MMP13*, were induced stronger in FOP-3DCI pellets than in resFOP-3DCI pellets (Fig. 4*C* and *SI Appendix, Fig. S9*). In addition, we observed that FK506 treatment enhanced chondrogenesis in resFOP-3DCI pellets treated with Activin-A (*SI Appendix, Fig. S10*). These results indicated that Activin-A treatment enhanced chondrogenic differentiation in FOP-3DCI pellets in vitro.

Chondrogenesis is a critical step in endochondral ossification through which ectopic bones are formed in FOP patients. To further characterize the FOP-3DCI pellets, we subcutaneously transplanted the pellets into the backs of immunodeficient mice and observed whether calcification without stimulus occurred. Before transplantation, no calcification was observed in 3DCI pellets (*SI Appendix, Fig. S11*). Four weeks after transplantation, X-ray photos showed a dense radiopaque mass in 9 of 10 mice transplanted with FOP-3DCI pellets, but only 1 in 10 mice transplanted with resFOP-3DCI pellets (Fig. 4*D* and *SI Appendix, Fig. S12A*). Microcomputed tomography (μ CT) images showed multiple calcified nodules in the entire mass (Fig. 4*E* and *SI Appendix, Fig. S12B*). Histological analyses revealed enlarged chondrocytes surrounded by a calcified matrix (Fig. 4*F*), which closely resembled the calcified zone in growth plates. Contribution of transplanted cells to the central cartilaginous zone was confirmed by immunostaining with anti-human nuclei antibody (HNA), whereas HNA-positive and -negative cells were detected in the surface calcified zone, indicating the contribution of both transplanted human cells and host mouse cells. Because 3DCI pellets were no longer exposed to exogenous Activin-A after transplantation, these results indicated that FOP-3DCI pellets spontaneously proceeded to the last step of differentiation of growth plate chondrocytes in vivo.




Fig. 4. Enhanced chondrogenesis of 3DCI pellets of FOP-iMSCs by Activin-A stimulation, which spontaneously calcified in vivo. (A) GAG/DNA of 3DCI pellet from FOP- and resFOP-iMSCs cultured with Activin-A (ActA), BMP-7 (BMP), or TGF- β 3 (TGF) at day 17. (B and C) 3DCI pellet assay from FOP- and resFOP-iMSCs cultured with Activin-A at day 21. (B) Alcian blue staining of FOP- and resFOP-3DCI pellets. [Scale bars, 200 μ m (Upper); 50 μ m (Lower).] (C) Higher expression levels of late chondrogenic markers were seen in the FOP-3DCI pellets. (D–F) FOP-3DCI pellets spontaneously calcified in vivo. FOP- or resFOP-3DCI pellets cultured for 21 d with Activin-A were subcutaneously transplanted in NOD/ShiJic-scid Jcl (NOD/SCID) mice. Ten mice were transplanted with both FOP-3DCI (right side) and resFOP-3DCI pellets (left side) for 28 d. (D) Number of FOP- or resFOP-3DCI pellets calcified in vivo assessed by X-ray imaging. (E) A μ CT image shows a calcified FOP-3DCI pellet (red arrow). (F) Histological analysis of transplanted FOP-3DCI pellets. H&E, Alcian blue staining (sulfated polysaccharides), von Kossa staining (calcium), and anti-human nuclei staining are shown. [Scale bars, 200 μ m (Upper); 100 μ m (Lower).] Results are the mean $\pm$ SE. $n = 3$ (A and C). n.s., no significant difference; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ by Student's *t* test compared with resFOP treated with the same ligands (A and C).

Activin-A Induces Endochondral Ossification of FOP-iMSCs in Vivo.

Finally, to investigate whether Activin-A can induce heterotopic endochondral ossification of FOP-iMSCs in vivo, FOP- and resFOP-iMSCs were transplanted into the gastrocnemius muscle of NOD/SCID mice with C3H10T1/2 harboring Doxycycline (Dox)-inducible Activin-A. Six weeks after transplantation, only the combination of FOP-iMSCs and Activin-A expression induced HO in the injected site (Fig. 5*A* and *B* and *SI Appendix, Fig. S13*). Histological analyses revealed that without Dox, transplanted iMSCs contributed to fibrous tissue in the muscle (Fig. 5*C*) [Dox (–) groups]. After Dox induction, resFOP-iMSCs contributed to GAG-rich mature chondrocytes, whereas no calcification was observed (Fig. 5*C*) [Dox (+), resFOP]. In the Dox (+) FOP group, cartilaginous tissue resembling hypertrophic and calcified chondrocytes was observed, consistent with the result of FOP-3DCI pellets (Fig. 4*B* and *F*). Furthermore, we observed calcified tissue neighboring the cartilaginous site, where expression of COL1, a marker of bone formation, was found (Fig. 5*C*) [Dox (+), FOP]. Finally, cartilaginous and calcified cells were




Fig. 5. Transplanted FOP-iMSCs were ossified in vivo by Activin-A stimulation. (A–C) FOP- (right leg) and resFOP-iMSCs (left leg) were transplanted into the gastrocnemius muscle of NOD/SCID mice with Dox-inducible Activin-A expressing C3H10T1/2. Transplanted cells were analyzed 6 wk after transplantation. (A) X-ray and μ CT images. Red arrows show FOP-iMSCs derived bone. (Scale bars, 10 mm.) (B) Heterotopic bone volume (cm^3) of each group. Results are the mean $\pm$ SE. $n = 3$. n.s., no significant difference; *** $P < 0.001$ by Student's t test compared with resFOP transplanted tissue. (C) Histological analysis of FOP- and resFOP-iMSCs derived tissue. HE, Safranin O, von Kossa, anti-human nuclei staining, and anti-COL1 staining are shown. (Scale bars, 100 μm .)

both HNA⁺. Taken together, these data indicate Activin-A induces heterotopic endochondral ossification in FOP in vivo.

Discussion

Taking advantage of MSCs derived from patient-derived iPSCs, we here present a novel in vivo model of FOP to evaluate the role and mechanism of action of Activin-A in HO. Only FOP-iMSCs cotransplanted with Activin-A-expressing C3H10T1/2 cells in NOD/SCID mice showed bone and cartilage formation (Fig. 5), clearly demonstrating the contribution of Activin-A to endochondral ossification of FOP-cells in vivo. Although Activin-A also induced extracellular matrix-rich cartilage in resFOP-iMSCs, hypertrophic chondrocytes were found in FOP-iMSCs but not in resFOP-iMSCs, indicating that FOP-ACVR1 with Activin-A accelerated the terminal differentiation of chondrocytes. Intriguingly, FOP-3DCI pellets were calcified in vivo without exogenous ligand stimulation, suggesting that Activin-A is not essential for the late steps of HO. Indeed, administration of Activin-A with transplants (Activin-A soaked with Gelfoam) did not accelerate the calcification of FOP-3DCI pellets according to X-ray observations (SI Appendix, Fig. S14). HO in FOP patients can be divided into two phases, inflammation and destruction of connective tissues (phase 1) and bone formation

(phase 2) (5). The latter can be further subdivided into three stages: fibroproliferation and angiogenesis (2A), chondrogenesis (2B), and osteogenesis (2C). Our data indicated that Activin-A plays a critical role in stage 2B, but neither in stage 2A, because DNA content did not increase in FOP-iMSCs after Activin-A treatment (SI Appendix, Fig. S15), nor in stage 2C, as the in vivo treatment of Activin-A of FOP-3DCI pellets did not enhance calcification. We expect that, similar to the findings of stage 2B in the present work, our FOP-iPSCs can be used to study the signaling mechanisms that contribute to phase 1 and stages 2A and 2C.

Most recently, it was reported that neutralizing antibody against Activin-A suppresses HO in R206H-ACVR1 knock-in mouse by Hatsell et al. (41). This finding supports our study, which suggests Activin-A is a crucial trigger for HO in both FOP model mice and FOP patients, and modulating Activin-A/FOP-ACVR1 signaling is a promising drug target for FOP. In the Hatsell et al. report, however, FK506 did not endow Activin-A responsiveness in WT-ACVR1 overexpressing cells, whereas we show that FK506 conferred Activin-A-dependent activation of BMP signaling in resFOP-iMSCs and enhanced 3D chondrogenesis (Fig. 2G and SI Appendix, Fig. S10). This discrepancy might be because of the different concentrations of FK506 tested.

The current prevailing concept of the FOP pathology is that missense mutations endow ACVR1 with constitutive activity or hyperactivity after ACVR1 binds to BMP. In the present report, we demonstrated a novel third mechanism, where FOP-ACVR1 transduces BMP signaling in response to Activin-A. In FOP-iMSCs, Activin-A transduced both TGF- β and BMP signaling through ACVR1B and FOP-ACVR1, respectively. This conclusion was supported by unbiased transcriptome analyses, which suggested that during chondrogenesis, Activin-A stimulation induced the dual activation of BMP and TGF- β signaling in FOP-iMSCs. Consistently, we found administration of either SB431542 or DMH1, specific inhibitors of TGF- β and BMP, respectively, abrogated the enhanced chondrogenesis in FOP-iMSCs. Based on these observations, we propose that enhanced chondrogenesis in FOP-iMSCs by Activin-A treatment is a result of abnormal activation of BMP signaling along with normal TGF- β signaling. More intriguingly, this neofunction could disrupt tissue homeostasis by dysregulating BMP signaling intensity. This intensity is stabilized via transcriptional negative feedback loops (33). For example, *GREM1* is known to be a downstream gene of BMP signaling, and its protein functions as a BMP ligand antagonist (32, 33, 42). Consistent with our findings, Activin-A stimulation in FOP-iMSCs induced stronger expression of *GREM1* than that in resFOP-iMSCs (SI Appendix, Fig. S16). Importantly, *GREM1* does not antagonize Activin-A signaling (42). These results suggest that Activin-A-stimulated BMP signaling in FOP-iMSCs is outside the negative feedback regulation loops network. Therefore, aberrant induction and escaping from negative feedback regulation should be hallmarks of BMP signaling in FOP, which stimulates the formation of ectopic bones. Understanding how canonical ligands and noncanonical ligands, as demonstrated in this report, are involved in the activation of BMP signaling in the clinical situation, remains an important issue awaiting future clarification.

Materials and Methods

Full experimental procedures and associated references are available in SI Appendix, SI Materials and Methods.

Cell Culture. The induction and maintenance of induced neural crest cells (iNCCs) and iMSCs derived from iPSC were previously described (43). FOP-iPSCs used in this study [FOP-iPSCs from patient 1 and 2, previously described as vFOP4-1 and vFOP5-22 (25), respectively] harbor the R206H heterozygous mutation in ACVR1, and gene-corrected resFOP-iPSCs were generated by BAC-based homologous recombination (26). All experiments shown in Figs. 1–5 were performed using FOP-iPSCs from patient 1 and resFOP-iPSCs (cl1) (26).

FOP-ACVR1 Specific Ligand Screening. FOP- and resFOP-iMSCs transiently transfected with BRE-Luc and CMV-*Renilla* were seeded into 384-well plates

and treated with TGF- β superfamily ligands. After 16-h incubation, relative luciferase units (RLU) were measured. In Fig. 1B, the highest concentrations tested in *SI Appendix, Fig. S1* are shown.

Two-Dimensional Chondrogenic Induction. iMSCs (1.5×10^5) were suspended in 5 μ L of chondrogenic basal medium and subsequently transferred to fibronectin-coated 24-well plates (BD Biosciences). After 1 h, a total of 1 mL of the chondrogenic basal medium supplemented with several ligands or inhibitors was added. Micromass cultures were maintained at 37 °C under 5% (vol/vol) CO₂ for 7 d.

Three-Dimensional Chondrogenic Induction. iMSCs (2.5×10^5) were suspended in chondrogenic basal medium supplemented with 100 ng/mL Activin-A, 100 ng/mL BMP-7, or 10 ng/mL TGF- β 3, and subsequently transferred to PrimeSurface 96U (Sumitomo Bakelite) (Fig. 4A) or 15-mL tubes (Corning). Cells were centrifuged to form pellets and maintained at 37 °C under 5% (vol/vol) CO₂. The culture medium was changed every 2–3 d.

In Vivo Calcification of 3DCI Pellets. The 3DCI pellets cultured with 100 ng/mL Activin-A for 21 d in vitro were wrapped in 0.5 cm $\times$ 1 cm Gelfoam (Pfizer) and transplanted beneath the dorsal skin of immunodeficient NOD/SCID mice (CLEA Japan) (44). Four weeks later, transplanted 3DCI pellets were harvested and analyzed.

iMSCs Transplantation with Activin-A-Producing Cells. FOP- (right leg) and resFOP-iMSCs (left leg) (4×10^6 , respectively) were transplanted into the gastrocnemius muscle of NOD/SCID mice with C3H-DoxOn-h1NHBA (5×10^5), which

can achieve continuous exposure of Activin-A on transplanted iMSCs in vivo by administration of Dox. Six weeks after transplantation, transplanted cells were harvested and analyzed.

Study Approval. All experimental protocols dealing with human subjects were approved by the Ethics Committee of the Department of Medicine and Graduate School of Medicine, Kyoto University. Written informed consent was provided by each donor. All animal experiments were approved by the institutional animal committee of Kyoto University.

ACKNOWLEDGMENTS. We thank Dr. S. Kawai for preparing patients' samples; Ms. Y. Tezuka for the microarray experiments; Dr. H. Sakurai for kind advice about immunostaining; Dr. K. Woltjen for providing the PB-TAC-ERN vector; Dr. H. Matsushita and the Center for Anatomical, Pathological, and Forensic Medical Researches, Kyoto University Graduate School of Medicine, for preparing microscope slides; Dr. A. Ikeda for invaluable comments and discussion; Drs. C. Alev and P. Karagiannis for reading the manuscript; Dr. S. Yamanaka for supporting/initiating fibrodysplasia ossificans progressiva research; and members of the J.T. and M.I. laboratories for their support during this study. This work was supported by Grants-in-aid for Scientific Research from The Japan Society for the Promotion of Science (#23791636, #25293320); the Leading Project for Realization of Regenerative Medicine from MEXT; in part by the Program for Intractable Diseases Research utilizing Disease-specific iPS cells from The Japan Science and Technology Agency and iPS Cell Research Fund (to M.I. and J.T.); and A-STEP, Adaptable and Seamless Technology Transfer Program through target-driven R&D, Exploratory Research (M.I.).

- Kaplan F, et al. (2005) The phenotype of fibrodysplasia ossificans progressiva. *Clin Rev Bone Miner Metab* 3(3-4):183–188.
- Shore E, Feldman G, Xu M, Kaplan F (2005) The genetics of fibrodysplasia ossificans progressiva. *Clin Rev Bone Miner Metab* 3(3-4):201–204.
- Kaplan FS, Groppe J, Pignolo RJ, Shore EM (2007) Morphogen receptor genes and metamorphogenesis: Skeleton keys to metamorphosis. *Ann N Y Acad Sci* 1116:113–133.
- Kaplan FS, et al. (2008) Fibrodysplasia ossificans progressiva. *Best Pract Res Clin Rheumatol* 22(1):191–205.
- Shore EM, Kaplan FS (2010) Inherited human diseases of heterotopic bone formation. *Nat Rev Rheumatol* 6(9):518–527.
- Kaplan FS, Chakkalakal SA, Shore EM (2012) Fibrodysplasia ossificans progressiva: Mechanisms and models of skeletal metamorphosis. *Dis Model Mech* 5(6):756–762.
- Shore EM, et al. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat Genet* 38(5):525–527.
- Urist MR (1965) Bone: Formation by autoinduction. *Science* 150(3698):893–899.
- Wozney JM, et al. (1988) Novel regulators of bone formation: Molecular clones and activities. *Science* 242(4885):1528–1534.
- Mueller TD, Nickel J (2012) Promiscuity and specificity in BMP receptor activation. *FEBS Lett* 586(14):1846–1859.
- Kaplan FS, et al. (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. *Hum Mutat* 30(3):379–390.
- Chaikwad A, et al. (2012) Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. *J Biol Chem* 287(44):36990–36998.
- Fukuda T, et al. (2008) A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. *Biochem Biophys Res Commun* 377(3):905–909.
- Fukuda T, et al. (2009) Constitutively activated ALK2 and increased SMAD1/5 co-operatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. *J Biol Chem* 284(11):7149–7156.
- Shen Q, et al. (2009) The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. *J Clin Invest* 119(11):3462–3472.
- Song GA, et al. (2010) Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. *J Biol Chem* 285(29):22542–22553.
- van Dinther M, et al. (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. *J Bone Miner Res* 25(6):1208–1215.
- Ohte S, et al. (2011) A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. *Biochem Biophys Res Commun* 407(1):213–218.
- Le VQ, Wharton KA (2012) Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a *Drosophila* model for classic fibrodysplasia ossificans progressiva. *Dev Dyn* 241(1):200–214.
- Bagarova J, et al. (2013) Constitutively active ALK2 receptor mutants require type II receptor cooperation. *Mol Cell Biol* 33(12):2413–2424.
- Chakkalakal SA, et al. (2012) An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. *J Bone Miner Res* 27(8):1746–1756.
- Culbert AL, et al. (2014) ALK2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification. *Stem Cells* 32(5):1289–1300.
- Billings PC, et al. (2008) Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). *J Bone Miner Res* 23(3):305–313.
- Hamasaki M, et al. (2012) Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: Mechanisms of reprogramming and strategy for drug identification. *Stem Cells* 30(11):2437–2449.
- Matsumoto Y, et al. (2013) Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. *Orphanet J Rare Dis* 8:190.
- Matsumoto Y, et al. (2015) New protocol to optimize iPS cells for genome analysis of fibrodysplasia ossificans progressiva. *Stem Cells* 33(6):1730–1742.
- Hogan BL (1996) Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. *Genes Dev* 10(13):1580–1594.
- Gu Z, et al. (1999) The type I serine/threonine kinase receptor ActR1A (ALK2) is required for gastrulation of the mouse embryo. *Development* 126(11):2551–2561.
- Mishina Y, Crombie R, Bradley A, Behringer RR (1999) Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis. *Dev Biol* 213(2):314–326.
- Massagué J, Blain SW, Lo RS (2000) TGF β signaling in growth control, cancer, and heritable disorders. *Cell* 103(2):295–309.
- Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic protein receptors and signal transduction. *J Biochem* 147(1):35–51.
- Piek E, Heldin CH, Ten Dijke P (1999) Specificity, diversity, and regulation in TGF- β superfamily signaling. *FASEB J* 13(15):2105–2124.
- Canalis E, Economides AN, Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. *Endocr Rev* 24(2):218–235.
- Renlund N, O'Neill FH, Zhang L, Sidis Y, Teixeira J (2007) Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of Activin to its type II receptor. *J Endocrinol* 195(1):95–103.
- Phillips DJ, de Kretser DM, Hedger MP (2009) Activin and related proteins in inflammation: Not just interested bystanders. *Cytokine Growth Factor Rev* 20(2):153–164.
- Antisferova M, Werner S (2012) The bright and the dark sides of Activin in wound healing and cancer. *J Cell Sci* 125(Pt 17):3929–3937.
- Groppe JC, Wu J, Shore EM, Kaplan FS (2011) In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. *Cells Tissues Organs* 194(2-4):291–295.
- Martin B, et al. (1992) Selective synthetic ligands for human nuclear retinoic acid receptors. *Skin Pharmacol* 5(1):57–65.
- Shimono K, et al. (2011) Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor- γ agonists. *Nat Med* 17(4):454–460.
- Zuscik MJ, Hilton MJ, Zhang X, Chen D, O'Keefe RJ (2008) Regulation of chondrogenesis and chondrocyte differentiation by stress. *J Clin Invest* 118(2):429–438.
- Hatsell SJ, et al. (2015) ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to Activin A. *Sci Transl Med* 7(303):303ra137.
- Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM (1998) The *Xenopus* dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. *Mol Cell* 1(5):673–683.
- Fukuta M, et al. (2014) Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. *PLoS One* 9(12):e112291.
- Yokoyama K, et al. (2015) Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. *Arthritis Rheumatol* 67(1):302–314.

Supporting Information (SI Appendix)

Neofunction of ACVR1 in fibrodysplasia ossificans progressiva

Kyosuke Hino, Makoto Ikeya, Kazuhiko Horigome, Yoshihisa Matsumoto, Hayao Ebise, Megumi Nishio, Kazuya Sekiguchi, Mitsuaki Shibata, Sanae Nagata, Shuichi Matsuda, and Junya Toguchida

SI Materials and Methods

SI References

SI Figures

Fig. S1. Detailed data of FOP-ACVR1 specific ligand screening.

Fig. S2. Clone 2 of patient 1- and clone 1 and 2 of patient 2-derived FOP-iMSCs also transduced abnormal BMP signaling, but resFOP-iMSCs did not.

Fig. S3. Knock-down efficiencies of siRNAs.

Fig. S4. Overexpression of the FOP-ACVR1 (R206H) conferred Activin-A responsiveness in HEK293 and HepG2.

Fig. S5. Activin-A transduced TGF- β -SMAD2/3 signaling similarly in FOP- and resFOP-iMSCs.

Fig. S6. Activin-A transduces TGF- β -SMAD2/3 signaling through ACVR1B and ACVR2A in FOP-iMSCs.

Fig. S7. FK506 enhanced the constitutive activity of FOP-iMSCs.

Fig. S8. GAG/DNA in the micromass of FOP-iMSCs cultured with Activin-A was inhibited by RAR γ agonists.

Fig. S9. Expression levels of chondrogenic markers in FOP and resFOP-3DCI pellets cultured with Activin-A.

Fig. S10. FK506 treatment enhanced 3D chondrogenesis of resFOP-iMSCs treated with Activin-A.

Fig. S11. Histology of 3DCI pellets from FOP- and resFOP-iMSCs cultured with Activin-A (100 ng/ml).

Fig. S12. X-ray images and sectioned μ CT image of FOP-3DCI pellets spontaneously calcified in vivo.

Fig. S13. X-ray images of transplanted FOP- and resFOP-iMSCs with Dox-inducible Activin-A expressing cells 6 weeks after transplantation.

Fig. S14. Administration of Activin-A with transplants did not accelerate the calcification.

Fig. S15. GAG value (A) and GAG/DNA (C), but not DNA content (B) were enhanced in FOP-3DCI pellets cultured with Activin-A for 21 days.

Fig. S16. Activin-A stimulation induced the expression of *GREM1* in FOP-iMSCs higher than in resFOP-iMSCs.

Fig. S17. Dox concentration-dependent Activin-A production by C3H-DoxOn-hINHBA cells.

SI Tables

Table S1. siRNA sequences.

Table S2. Antibodies for western blotting and immunostaining.

Table S3. Primers for RT-qPCR.

SI Materials and Methods

TGF- β superfamily ligands and related reagents. All TGF- β superfamily ligands with the exception of Inhibin-A (Raybiotech Inc., Norcross, GA, USA), growth differentiation factor-15 (GDF-15; Abnova Corporation, Taipei, Taiwan) and GDF-6 and -7 (GeneTex Inc., Irvine, CA, USA) were purchased from R&D Systems Inc. (Minneapolis, KA, USA). FLRG, FST, Anti-Activin-A antibody, ACVR1-Fc, BMPR1-Fc, ACVR2A-Fc, ACVR2B-Fc and BMPR2-Fc were purchased from R&D Systems. DMH1 and CD437 were purchased from Tocris Bioscience (Bristol, UK). SB-431542, FK506, and R667 were purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO, USA), Apollo Scientific Ltd. (Cheshire, UK) and Toronto Research Chemicals Inc. (Ontario, Canada), respectively. Activin-A and BMP-7 were used at 100 ng/ml, and TGF- β 3 at 10 ng/ml unless otherwise noted.

Cell culture. iPSCs were maintained in primate ES cell medium (ReproCELL Incorporated, Tokyo, Japan) supplemented with 4 ng/mL recombinant human FGF2 (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The induction and maintenance of iNCCs and iMSCs were previously described (1). Briefly, iNCCs were maintained in chemically defined medium (CDM) supplemented with FGF2 and recombinant human EGF (R&D Systems), and we used up to 20 passages in this study. iMSCs were induced and maintained in α MEM (Invitrogen Co., Carlsbad, CA, USA) supplemented with 10% (v/v) FBS (Nichirei Inc., Tokyo, Japan), 5 ng/mL FGF2 and 0.5% penicillin and streptomycin (Invitrogen). FOP-iPSCs used in this study (FOP-iPSCs from patient 1 and 2, previously described as vFOP4-1 and vFOP5-22 (2), respectively) harbor the R206H heterozygous mutation in ACVR1, and gene-corrected resFOP-iPSCs were generated by

BAC-based homologous recombination (3). All experiments shown in Fig. 1-5 were performed using FOP-iPSCs from patient 1 and resFOP-iPSCs (cl1) (3). Other clones' data are shown in SI Appendix, Fig. S2. COS (monkey kidney cells), C3H10T1/2 (murine multipotent mesenchymal cells), U2OS (human osteosarcoma cells), HEK293 (human embryonic kidney cells) and HepG2 (human Hepatocellular carcinoma cells) were obtained from ATCC, and LentiX293T was obtained from Takara Bio Inc. (Shiga, Japan). Cells were maintained in DMEM (Nacalai Tesque, Inc., Kyoto, Japan) supplemented with 10% (v/v) FBS and 1 mM Na-pyruvate (Invitrogen) (COS and C3H10T1/2) or in DMEM (Sigma-Aldrich) supplemented with 10% (v/v) FBS (U2OS, HEK293, HepG2 and LentiX293). To prepare C3H10T1/2-expressing Dox-inducible hINHBA (C3H-DoxOn-hINHBA), we inserted hINHBA cDNA into PB-TAC-ERN (KW111), which constitutively expresses the neomycin (G418) resistance gene along with the rtTA transactivator element and mediates doxycycline (Dox)-dependent activation of hINHBA controlled by tetO promoter (PB-TAC-ERN-hINHBA) (4, 5). After transfecting PB-TAC-ERN-hINHBA vector into C3H10T1/2, the neomycin-resistant population was selected. Activin-A production in vitro was confirmed by ELISA (SI Appendix, Fig. S17).

Luciferase assay. The BRE-Luc reporter was purchased from Addgene (Cambridge, MA, USA) (6). The CAGA-Luc reporter was constructed as previously described (7). The pRL-CMV renilla luciferase reporter (Promega Corporation, Madison, WI, USA) was transiently transfected and used for normalization. Expression vectors for FOP mutant receptors were constructed using the KOD-Plus-Mutagenesis Kit (TOYOBO CO., LTD., Osaka, Japan) and inserted into a pcDNATM-DEST40 vector. For transient expression,

FuGene® HD (Promega) or Lipofectamine® 2000 (Invitrogen, for RNAi experiments) were used according to the manufacturer's instructions. Luciferase activity was measured using the dual luciferase reporter assay system (Promega), and the luminescence signal was measured on EnVision® Multilabel Reader (PerkinElmer Co., Ltd, Waltham, MA, USA) according to the manufacturer's instructions. siRNAs specific for type I or II receptors were purchased from Thermo Fisher Scientific Inc. (Silencer® Select Pre-designed siRNA, Waltham, MA, USA) . Sequence information is shown in Table S1. For inhibition assay with Fc-fusion receptors, Activin-A (final 30 ng/mL) was incubated with Fc-fusion receptors (final concentrations of 0.1, 1 and 10 µg/mL) for 2 hours at 37 °C under 5% CO₂, and Activin-A and Fc-fusion receptors were added to FOP-iMSCs transiently transfected with BRE-Luc and CMV-Renilla.

Western Blotting. SDS-PAGE and blotting with whole-cell lysates were performed by standard procedures. Protein bands were detected with ECL Prime Western Blotting Detection Reagent (GE Healthcare, Little Chalfont, UK) and visualized using BIO-RAD Molecular Imager® Chemi-Doc™ XRS+ with Image Lab™ software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The antibodies used in this study are described in Table S2.

Quantitative PCR analysis. Total RNA was purified with the RNeasy Kit (Qiagen Inc., Valencia, CA, USA) and treated with the DNase-one Kit (Qiagen) to remove genomic DNA. Total RNA (0.3 µg) was reverse transcribed for single-stranded cDNA using random primers and Superscript III reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Quantitative PCR was performed with Thunderbird SYBR

qPCR Mix (TOYOBO) and analyzed with the StepOne real-time PCR system (Applied Biosystems, Waltham, MA, USA). Primer sequences are described in Table S3. 3D chondrogenic differentiated pellets were homogenized by Multi-Beads Shocker (Yasui Kikai Corporation, Osaka, Japan) according to the manufacturer's instructions.

Microarray experiments. To show the general activation of BMP downstream genes in FOP-iMSCs by Activin-A treatment, FOP- and resFOP-iMSCs were stimulated with 100 ng/mL Activin-A, 100 ng/mL BMP-7 or 10 ng/mL TGF- β 3, and after 16 hours incubation, mRNA was extracted. To analyze the enhanced chondrogenesis in FOP-iMSCs by Activin-A treatment at the molecular level, 2D chondrogenic induction was performed in FOP- and resFOP-iMSCs stimulated with or without 100 ng/mL Activin-A. After 7 days incubation, mRNA was extracted. RNA was reverse transcribed, biotin-labeled and hybridized to Human Genome U133 Plus 2.0 Array (Fig. 1F-I) or GeneChip Human Gene 1.0 ST Expression Array (Fig. 3D), which were subsequently washed and scanned according to the manufacturer's instructions (Affymetrix, Inc., Santa Clara, CA, USA). Raw CEL files were imported into GeneSpring GX 12.6.1 software (Agilent Technologies, Santa Clara, CA, USA), and expression values were calculated with the MAS 5.0 algorithm (Fig. 1F-I) or RMA16 algorithm (Fig. 3D). PCA and hierarchical clustering were analyzed by GeneSpring GX. Pathway analysis and upstream analysis were performed by Ingenuity pathway analysis (Qiagen).

Binding and Affinity Cross-linking. A SNAP-tag (New England Biolabs, Ipswich, MA, USA) or V5-tag was fused in-frame to the N terminus of hACVR2A and hACVR2B or C terminus of hACVR1, respectively, and inserted into a pLentiTO vector (Thermo Fisher Scientific). Recombinant human Activin-A was iodinated using Pierce Pre-Coated

Iodination Tubes (Thermo Fisher Scientific) according to the manufacturer's instructions. Receptors were transiently transfected into LentiX293T cells by TransIT®-293 Transfection Reagent (Mirus Bio LLC., Madison, WI, USA). After 48 h incubation, cells were washed with PBS and incubated with ^{125}I -Activin-A in PBS for 1 h at room temperature. After washes with PBS, cells were incubated with 0.5 mM disuccinimidyl suberate in HBSS for 1 h at room temperature, with TBS for 30 min at 4 °C and solubilized in 1% (v/v) TritonX100 in TBS. Protein bands were visualized using Typhoon FLA 7000 (GE Healthcare).

2D chondrogenic induction. 2D chondrogenic induction was performed using a previously described protocol with modification (8). Briefly, iMSCs (1.5×10^5) were suspended in 5 μL of chondrogenic basal medium (DMEM: F12 (Invitrogen), 1% (v/v) ITS + Premix (BD Biosciences), 0.1 μM dexamethasone (WAKO), 0.17 mM AA2P (Sigma-Aldrich), 0.35 mM Proline (Sigma-Aldrich), 0.15% (v/v) glucose (Sigma-Aldrich), 1 mM Na-pyruvate, 2 mM GlutaMax-I (Invitrogen) and 1% (v/v) FBS) and subsequently transferred to fibronectin-coated 24-well plates (BD Biosciences). After 1 h, a total of 1 mL of the chondrogenic basal medium supplemented with several ligands or inhibitors was added. Micromass cultures were maintained at 37 °C under 5% CO_2 for 7 days. Differentiation properties were assayed by qPCR analysis, GAG quantification and Alcian Blue staining (9). Briefly, induced cells were fixed for 30 minutes with 4% paraformaldehyde (WAKO) and rinsed with PBS. These cells were then stained overnight with Alcian Blue solution (1% Alcian Blue, pH 1 (MUTO PURE CHEMICAL CO., LTD, Tokyo, Japan) and destained with acetic acid solution.

3D chondrogenic induction. 3D chondrogenic induction (3DCI) was performed using a previously described protocol with modification (8). Briefly, iMSCs (2.5×10^5) were suspended in 0.5 mL of chondrogenic basal medium supplemented with 100 ng/mL Activin-A, 100 ng/mL BMP-7 (BMP) or 10 ng/mL TGF- β 3 (TGF), and subsequently transferred to PrimeSurface 96U (Sumitomo Bakelite Co., Ltd., Tokyo, Japan) (Fig. 4A) or 15 mL tubes (Corning Inc., Corning, NY, USA). Cells were centrifuged to form pellets and maintained at 37 °C under 5% CO₂. The culture medium was changed every 2-3 days. Fixation and staining of the 3DCI pellet cultures were performed as previously described (8).

GAG value. The GAG content was quantified in pellets with the Blyscan Glycosaminoglycan Assay Kit (Biocolor Ltd., Belfast, UK). The DNA content was quantified using the PicoGreen dsDNA Quantitation Kit (Invitrogen).

Immunohistochemistry. Paraffin-embedded sections were deparaffinized, and for human specific Anti-Nuclei Antibody, antigen retrieval was performed by microwave (300 W, 20 min). Samples were blocked with Blocking One (Nacalai Tesque, Inc.) for 60 min and then incubated with human specific Anti-Nuclei Antibody (EMD Millipore Corporation, Billerica, MA, USA) or Collagen I Antibody (Novus Biologicals, Littleton, CO, USA) diluted in Can Get Signal ® immunostain solution B (TOYOBO) for 16-18 h at 4 °C. Next, samples were washed several times in 0.2% tween20 (Sigma-Aldrich) in PBS and incubated with Goat anti-Mouse IgG1 Secondary Antibody Alexa Fluor® 568 conjugate (Invitrogen) or Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor® 488 conjugate (Invitrogen) diluted in Can Get Signal ® immunostain solution B for 1 h at room temperature. DAPI (10 µg/mL) was used to counterstain nuclei. Samples

were observed by BZ-9000E (KEYENCE CORPORATION, Osaka, Japan).

In vivo calcification of 3DCI pellets. 3DCI pellets cultured with 100 ng/mL Activin-A for 21 days in vitro were wrapped in 0.5 cm x 1 cm Gelfoam® (Pfizer Inc., New York, NY, USA) and transplanted beneath the dorsal skin of immunodeficient NOD/ShiJic-scid Jcl (NOD/SCID) mice (CLEA Japan, Inc., Tokyo, Japan) (10). Four weeks later, transplanted 3DCI pellets were harvested, fixed with 4% paraformaldehyde for 24 h, embedded in paraffin, sectioned and stained with HE, von Kossa, Alcian blue, as previously reported (8), and human specific Anti-Nuclei Antibody. For X-ray images, mice were anesthetized with isoflurane (Abbvie Limited, Berkshire, UK), immobilized and X-rayed using μ FX-1000 (Fujifilm Corporation, Tokyo, Japan) at 50 kV, 100 μ A. Transplanted 3DCI pellets were scanned using X-ray CT systems (Fig. 4E: Latheta LCT-200, Hitachi Aloka Medical, Ltd., Tokyo, Japan; SI Appendix, Fig. S12B: inspeXio SMX-100CT, Shimadzu Corporation, Kyoto, Japan) and analyzed by VGStudio MAX 2.0 (Volume Graphics GmbH, Heidelberg, Germany) according to the manufacturer's instructions.

iMSCs transplantation with Activin-A producing cells. FOP- (right leg) and resFOP-iMSCs (left leg) (4×10^6 respectively) were transplanted into the gastrocnemius muscle of NOD/SCID mice with C3H-DoxOn-hINHBA (5×10^5), which can achieve continuous exposure of Activin-A on transplanted iMSCs in vivo. In the Dox-induced group, 1 mg/mL Dox (Sigma-Aldrich) was administered via drinking water with 10 mg/mL sucrose (Nacalai Tesque, Inc.) for two weeks following transplantation. Six weeks after transplantation, transplanted cells were analyzed. μ CT images were scanned

using inspeXio SMX-100CT, and bone volume was analyzed by TRI/3D-BON (Ratoc System Engineering Co., Ltd., Tokyo, Japan) according to the manufacturer's instructions. Transplanted cells were harvested, fixed with 4% paraformaldehyde for 24 h, embedded in paraffin, and sectioned and stained with HE, von Kossa, Safranin O, human specific Anti-Nuclei Antibody and Collagen I Antibody. Safranin O staining was performed using the Safranin O Stain Kit (IHC WORLD, LLC., Ellicott, MD, USA) according to the manufacturer's instructions.

Statistics. The statistical significance of all experiments was calculated by Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). P values less than 0.05 were considered statistically significant.

SI References

1. Fukuta M, *et al.* (2014) Derivation of Mesenchymal Stromal Cells from Pluripotent Stem Cells through a Neural Crest Lineage using Small Molecule Compounds with Defined Media. *PloS one* 9(12):e112291.
2. Matsumoto Y, *et al.* (2013) Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. *Orphanet J Rare Dis* 8:190.
3. Matsumoto Y, *et al.* (2015) New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva. *Stem Cells*.
4. Woltjen K, *et al.* (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458(7239):766-770.
5. Tanaka A, *et al.* (2013) Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. *PloS one* 8(4):e61540.
6. Korchynskiy O & ten Dijke P (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. *J Biol Chem* 277(7):4883-4891.
7. Dennler S, *et al.* (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J* 17(11):3091-3100.
8. Umeda K, *et al.* (2012) Human chondrogenic paraxial mesoderm, directed specification and prospective isolation from pluripotent stem cells. *Scientific reports* 2:455.
9. Nasu A, *et al.* (2013) Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin. *PloS one* 8(1):e53771.
10. Yokoyama K, *et al.* (2015) Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. *Arthritis Rheumatol* 67(1):302-314.




Fig. S1. Detailed data of FOP-ACVR1 specific ligand screening. FOP- and resFOP-iMSCs transiently transfected with BRE-Luc and CMV-Renilla were seeded into 384 well plates, and stimulated by ligands. After 16 hours incubation, luciferase activity was measured. Results are the mean $\pm$ standard error (SE). N = 3-4.




Fig. S2. Clone 2 of patient 1- and clones 1 and 2 of patient 2-derived FOP-iMSCs transduced abnormal BMP signaling, but resFOP-iMSCs did not. (A) BRE-Luc activity in FOP- and resFOP-iMSCs from clone 2 of patient 1 stimulated by Activin-A or 10 ng/mL BMP-4. (B) BRE-Luc activity in FOP- and resFOP-iMSCs from patient 2 stimulated by Activin-A or BMP-7. Results are the mean $\pm$ standard error (SE). N = 4. n.s., no significant difference; *, $P < 0.05$; ***, $P < 0.001$ by Dunnett's multiple comparisons t -test compared to the no ligand treatment control. Note all experiments in Fig. 1-5 were performed using FOP- and resFOP clone 1 from patient 1.





Fig. S3. Knock-down efficiencies of siRNAs. FOP-iMSCs transiently transfected with siRNAs specific for type I receptors or type II receptors were incubated for 16 hours, and RNA was extracted. N = 1.

A



B




Fig. S4. Overexpression of the FOP-ACVR1 (R206H) conferred Activin-A responsiveness in HEK293 and HepG2. Cells transiently transfected with BRE-Luc, CMV-Renilla and WT- or FOP-ACVR1 were stimulated with 50 ng/mL Activin-A or 100 ng/mL BMP-7 in HEK293 (A) or 50 ng/mL BMP-7 in HepG2 (B). Results are the mean $\pm$ standard error (SE). N = 2.




Fig. S5. Activin-A transduced TGF- β -SMAD2/3 signaling similarly in FOP- and resFOP-iMSCs. (A) Representative image of western blot analysis. Activin-A induced phosphorylation of SMAD2/3 similarly in FOP- and resFOP-iMSCs. ActA, 100 ng/mL Activin-A; TGF, TGF- β 3 10 ng/mL. (B) Quantification of phosphorylation levels. Activin-A, 100 ng/mL; TGF- β 3, 10 ng/mL. (C) Activin-A increased CAGA-Luc activity similarly in FOP- and resFOP-iMSCs. Cells were stimulated with ligands for 3 hours at 37 °C under 5% CO₂. Results are the mean $\pm$ standard error (SE). N = 3 (Western blot) or N = 4 (CAGA-Luc). n.s., no significant difference; *, P < 0.05; **, P < 0.01 by Student's *t*-test compared to the value of resFOP treated with the same condition.




Fig. S6. Activin-A transduces TGF- β -SMAD2/3 signaling through ACVR1B and ACVR2A in FOP-iMSCs. FOP-iMSCs transiently transfected with CAGA-Luc, CMV-Renilla and siRNAs specific for type I receptors (A) or type II receptors (B) were stimulated with Activin-A for 3 hours at 37 °C under 5% CO₂. Results are the mean $\pm$ standard error (SE). N = 4, n.s., no significant difference; *, P < 0.05; ***, P < 0.001 by Dunnett's multiple comparisons *t*-test compared to control siRNA transfected FOP-iMSCs.




Fig. S7. FK506 enhanced the constitutive activity of FOP-iMSCs. FOP-iMSCs transiently transfected with BRE-Luc and CMV-Renilla were treated with 1 μ M FK506 and/or Activin-A for 16 hours. Results are the mean $\pm$ standard error (SE). N = 4, ***, P < 0.001 by Turkey's multiple comparisons *t*-test.




Fig. S8. GAG/DNA in the micromass of FOP-iMSCs cultured with Activin-A was inhibited by $\text{RAR}\gamma$ agonists. Results are the mean $\pm$ standard error (SE). $N = 3$. n.s., no significant difference; ***, $P < 0.001$ by Dunnett's multiple comparisons t -test compared to Activin-A-treated micromass without $\text{RAR}\gamma$ agonists.




Fig. S9. Expression levels of chondrogenic markers in FOP and resFOP-3DCI pellets cultured with Activin-A. Results are the mean $\pm$ standard error (SE). N =4. n.s., no significant difference; *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Student's *t*-test compared to resFOP. resFOP (day8) was normalized to 1.





Fig. S10. FK506 treatment enhanced 3D chondrogenesis of resFOP-iMSCs treated with Activin-A. resFOP-3DCI pellets were cultured with FK506 and/or Activin-A for 21 days . Results are the mean $\pm$ standard error (SE). N = 4, n.s., no significant difference; **, P < 0.01; ***, P < 0.001 by Dunnett's multiple comparisons compared to the value of no FK506 treatment control of resFOP with the same Activin-A treatment.

A



B





Fig. S11. Histology of 3DCI pellets from FOP- and resFOP-iMSCs cultured with Activin-A (100 ng/ml). Each pellet was cultured for 21 days and examined with HE (A) or von Kossa (B) staining. Scale bars, 100 μ m.

A



B





Fig. S12 . X-ray images and sectioned μ CT image of FOP-3DCI pellets spontaneously calcified in vivo. (A) X-ray image of mice transplanted with FOP- and resFOP-3DCI pellets 4 weeks after transplantation. Red arrows show transplanted FOP-3DCI pellets, and the blue arrow shows transplanted resFOP-3DCI pellets. (B) The sectioned μ CT image shows a transplanted FOP-3DCI pellet.

Dox (-)



Dox (+)






Fig. S13. X-ray images of transplanted FOP- and resFOP-iMSCs with Dox-inducible Activin-A expressing cells 6 weeks after transplantation. Red arrows show FOP-iMSCs derived bone. N = 3.

A

PBS-soaked
Gelfoam®



Activin-A-soaked
Gelfoam®



B

5 week after transplantation	PBS-soaked Gelfoam®	Activin-A-soaked Gelfoam®
# of FOP-3DCI pellets calcified	5/5	3/5
# of resFOP-3DCI pellets calcified	0/5	0/5

Fig. S14. Administration of Activin-A with transplants did not accelerate the calcification. FOP- or resFOP-3DCI pellets cultured for 21 days with Activin-A (100 ng/ml) were mixed with PBS- or Activin-A (10 μ g/mL)-soaked Gelform® and then transplanted subcutaneously in the same NOD/ShiJic-scld Jcl (NOD/SCID) mice (N=5) at the right and left sides, respectively. (A) X-ray images of mice transplanted with FOP- and resFOP-3DCI pellets. Red arrows show transplanted FOP-3DCI pellets. (B) Number of calcified samples in FOP- or resFOP-3DCI pellets with either PBS- or Activin-A-soaked Gelform®. Calcification of pellets was assessed by X-ray imaging.

□ resFOP
■ FOP




Fig. S15. GAG values (A) and GAG/DNA (C), but not DNA content (B) were enhanced in FOP-3DCI pellets cultured with Activin-A for 21 days. Results are the mean $\pm$ standard error (SE). N = 3. ***, P < 0.001 by Dunnett's multiple comparisons *t*-test compared to resFOP.




Fig. S16. Activin-A stimulation induced the expression of *GREM1* in FOP-iMSCs higher than in resFOP-iMSCs. FOP- and resFOP-iMSCs were stimulated with 100 ng/mL Activin-A. After 16 hours incubation, mRNA was extracted and qPCR analysis was performed. Results are the mean $\pm$ standard error (SE). N =3. *, $P < 0.05$; ***, $P < 0.001$ by Student's t-test compared to the value of resFOP treated with the same condition.

Activin-A production (C3H-DoxOn-hINHBA)




Fig. S17. Dox concentration-dependent Activin-A production by C3H-DoxOn-hINHBA cells. Cells (5×10^5 cells in 12-well plates) were stimulated with Dox for 24 hours, and cultured supernatants were collected. The amount of Activin-A was analyzed by ELISA. Results are the mean $\pm$ standard error (SE). N = 3. n.s., no significant difference; ***, $P < 0.001$ by Dunnett's multiple comparisons t -test compared to Dox (-).

Table S1. siRNA sequences.

Gene	siRNA ID	Sense	Antisense
ACVRL1	s987	GGAUCAAGAAGACACUACAtt	UGUAGUGUCUUCUUGAUCCgc
ACVR1	s976	GUUGCUCUCCGAAAAUUUAAtt	UAAAUUUUCGGAGAGCAACtc
BMPR1A	s282	GAAUCUGGAUAGUAUGCUUtt	AAGCAUACUAUCCAGAUUCtg
ACVR1B	s977	AGUACUUGAUGAAACCAUUt	AAUGGUUUCAUCAAGUACUtc
TGFBR1	s229438	GGUCUGUGACUACAACAUAtt	UAUGUUGUAGUCACAGACCca
BMPR1B	s2041	GGACGAGAGCUUGAACAGAtt	UCUGUUCAAGCUCUCGUCCaa
ACVR2A	s981	GGAUGAUAUCAACUGCUAUtt	AUAGCAGUUGAUUAUCAUCCag
ACVR2B	s985	GCUCCAACCUCGAAGUAGAtt	UCUACUUCGAGGUUGGAGCct
BMPR2	s2046	GGACAAUAUUAUGCUCGAAtt	UUCGAGCAUAAUAUUGUCCca
TGFBR2	s14078	GGAGAAAGAAUGACGAGAAtt	UUCUCGUCAUUCUUUCUCCat

Table S2. Antibodies for western blotting and immunostaining.

	Name	Company	Cat. No	Concentration
1st antibody	Phospho-Smad1 (Ser463/465)/ Smad5 (Ser463/465) / Smad8 (Ser426/428) Antibody	Cell Signaling Technology	#9511L	1:1000
	Smad1/5/8 Antibody (N-18)-R	Santa Cruz Biotechnology	sc-6031-R	1:1000
	Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) (D27F4) Rabbit mAb	Cell Signaling Technology	#8828	1:1000
	Smad2/3 (D7G7) XP® Rabbit mAb	Cell Signaling Technology	#8685	1:1000
	Anti-Nuclei Antibody, clone 235-1	EMD Millipore	MAB1281	1:30
	Collagen I Antibody	Novus Biologicals	NB600-408	1:100
2nd antibody	Anti-rabbit IgG, HRP-linked Antibody	Cell Signaling Technology	#7074	1:100000
	Goat anti-Mouse IgG1 Secondary Antibody, Alexa Fluor® 568 conjugate	Invitrogen	A-21124	1:500
	Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor® 488 conjugate	Invitrogen	A-11008	1:500

Table S3. Primers for RT-qPCR.

Name	Forward	Reverse
<i>ACTB</i>	CACCATTGGCAATGAGCGGTTC	AGGTCTTTGCGGATGTCCACGT
<i>ACAN</i>	TCGAGGACAGCGAGGCC	TCGAGGGTGTAGCGTGTAGAGA
<i>COL2</i>	GGCAATAGCAGGTTCACGTACA	CGATAACAGTCTTGCCCCACTT
<i>SOX9</i>	GACTTCCGCGACGTGGAC	GTTGGGCGGCAGGTACTG
<i>NKX3-2</i>	GCCGCTTCCAAAGACCTAGAG	CCAACACCGTCGTCCTCG
<i>FGFR3</i>	AGTACCTGGACCTGTCGGC	CCTCACATTGTTGGGGACCA
<i>IHH</i>	CGGTGGACATCACCACATCA	CGTGGGCCTTTGACTCGTAA
<i>COMP</i>	CAACTGTCCCCAGAAGAGCAA	TGGTAGCCAAAGATGAAGCCC
<i>SP7</i>	ATCCAGCCCCCTTTACAAGC	TAGCATAGCCTGAGGTGGGT
<i>COL10A1</i>	CCCAGCACGCAGAATCCATC	AGTGGGCCTTTTATGCCTGT
<i>VEGFA</i>	CAATCGAGACCCTGGTGGAC	TCTCTCCTATGTGCTGGCCT
<i>RUNX2</i>	TTACTTACACCCCGCCAGTC	TATGGAGTGCTGCTGGTCTG
<i>MMP13</i>	CATGAGTTCGGCCACTCCTT	CCTGGACCATAGAGAGACTGGA
<i>ID1</i>	CCAACGCGCCTCGCCGGATC	CTCCTCGCCAGTGCCTCAG
<i>ID3</i>	CTGGACGACATGAACCACTG	GTAGTCGATGACGCGCTGTA
<i>GREM1</i>	CTCCTTCTGCAAGCCCAAGA	CAACGACACTGCTTCACACG
<i>ACVRL1</i>	CACGGACTGCTTTGAGTCCT	TCTGCTGATCCACACACACC
<i>ACVR1</i>	GCGGTAATGAGGACCACTGT	CCCTGCTCATAAACCTG
<i>BMPR1A</i>	AGCTACGCCGGACAATAGAA	AATGAGCAAAACCAGCCATC
<i>ACVR1B</i>	TGCTCGAAGATGCAATTCTG	AACCTTTCGCATTTCTCAA
<i>TGFBR1</i>	TGTAAAGTCATCACCTGGCCT	ATGGTGAATGACAGTGCGGT
<i>BMPR1B</i>	GTTCCCTTTATGATTATCTGAAGTCC	TTAGACACTCATCACTGCTCCAC
<i>ACVR1C</i>	GGTCGACAGTGCTCCTACAG	TCTTCCATGCCACACCTCAC
<i>ACVR2A</i>	ACACAGCCCACTTCAAATCC	AGGAGGGTSGGCCATCTTGT
<i>ACVR2B</i>	GATCTTCCCACTCCAGGACA	CTCGGCAGCAATGAAGTGA
<i>BMPR2</i>	GCTGTTGGGACCAGGATG	TTGCGTTCATTCTGCATAGC
<i>TGFBR2</i>	AGACGTTGACTGAGTGCTGG	TTAGGGAGCCGTCTTCAGGA
<i>AMHR2</i>	GGCCTATGAGGCAGAACTGG	CTCTTGAGGATGGGCCAAGG